Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article · Related *content* · Metrics ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  EurekAlert

Philadelphia, January 15, 2019 - A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology ...

Retinal Vein Occlusion Therapeutics Market to Reflect Steady Growth Rate by 2021 | Kentucky Breaking News Updates  Kentucky Journal 24

Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after ...

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Laser-induced chorioretinal anastomosis can lessen CRVO treatment burden  Healio

Adding laser-induced chorioretinal anastomosis to anti-VEGF treatment for central retinal vein occlusion can reduce the number of injections needed, according ...

Global Retinal Vein Occlusion Market 2019 – Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  MajoReports

The Global Retinal Vein Occlusion Market Report study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and ...

Retinal Vein Occlusion Therapeutics Market: Global Distributors, Traders and Dealers Marketing Channel Future Trend Prediction to 2025  Washington DC Herald

Global Retinal Vein Occlusion Therapeutics Market Insights, forecast to 2025 mainly highlights thoughtful facts and knowledge of Retinal Vein Occlusion ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 3.8% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. with ticker code (REGN) now have 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Northern Trust Corp Buys 22,468 Shares of Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

Northern Trust Corp grew its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 2.4% in the fourth quarter, according to the company in its most ...

CIExpert on Canada Life's individual CI upgrade | COVER  COVER

'Solid improvements that will increase claims paid,' says Alan Lakey.

Avastin as effective as Eylea for treating central retinal vein occlusion  National Institutes of Health

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

Researchers confirm link between retinal vein occlusion, heart attack  Cardiovascular Business

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Precise Analysis on Global Branch Retinal Vein Occlusion Clinical Trials Reviewed for H2, 2018  industrydailyobserver.com

The global market for Branch Retinal Vein Occlusion is likely to attain novel growth heights with fast transitioning end-user preferences. Burgeoning vegan ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

US, UK trials underway to compare treatments for CRVO  Healio

KOLOA, Hawaii — Not long ago, there were no effective treatments for central retinal vein occlusion; now there are multiple treatments, Michael S. Ip, MD, said at ...

Aflibercept Benefits Bevacizumab-Unresponsive Diabetic Retinopathy Patients  MD Magazine

A new analysis of an ongoing clinical study offers insights for treating retinal vein occlusion in poor responders to bevacizumab.

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Guggenheim Downgrades Regeneron Pharmaceuticals (REGN) to Neutral  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating in a research note issued to investors ...

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

CRYSTAL study shows good results of personalized anti-VEGF treatment regimen in CRVO  Healio

Two-year results of the CRYSTAL study show that an as-needed medication regimen with frequent monitoring can reduce the number of anti-VEGF injections ...

Intravitreal corticosteroid implant vs intravitreal ranibizumab for th | DDDT  Dove Medical Press

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials Qingquan Wei,1 ...

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment  Bel Marra Health

Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where the main vein of the retina has become blocked. Much like other organs of ...

Regeneron Pharmaceuticals (REGN) Price Target Increased to $480.00 by Analysts at Oppenheimer  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by research analysts at Oppenheimer from $440.00 to $480.00 in a research note ...

Regeneron Pharmaceuticals Inc (REGN) Major Shareholder Sanofi Sells 131,115 Shares of Stock  Fairfield Current

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) major shareholder Sanofi sold 131115 shares of the company's stock in a transaction that occurred on Friday ...

Global Retinal Vein Occlusion Therapeutics Market Current Outlook with Noted Manufactures are Sanofi Aventis,Valeant Pharmaceuticals,Allergan  RISReport

The Global Retinal Vein Occlusion Therapeutics Market Report provides Insightful information to the clients enhancing their basic leadership capacity identified ...

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and Forecast to 2023 |  Medgadget

Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Cheap Avastin as effective as Eylea in CRVO  European Biotechnology

A study conducted by an NIH institute proves Roche's Avastin is as effective as Regeneron's Eylea, a drug that costs 30 times more than Roche's antibody.

Regeneron Pharmaceuticals Inc (REGN) Receives Consensus Rating of “Hold” from Brokerages  Fairfield Current

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has earned a consensus recommendation of “Hold” from the twenty-six analysts that are presently covering ...

BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer  PRNewswire

BOULDER, Colo., March 18, 2019 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Sivik Global Healthcare LLC Purchases New Stake in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

Sivik Global Healthcare LLC purchased a new position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 4th quarter, according to the company in ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

SCORE2 subanalysis: Visual gains made after treatment switch  Healio

WAIKOLOA, Hawaii — Visual acuity letter score and central subfield thickness both improved in eyes treated with aflibercept after a poor response to ...

Laser Speckle Flowgraphy Can Assist in CRVO Prognosis  Medscape

Laser speckle flowgraphy may offer a noninvasive method of assessing ocular blood flow in patients with central retinal vein occlusion (CRVO), according to a ...

VIDEO: SCORE2 and LEAVO trials underway to compare CRVO treatments  Healio

KOLOA, Hawaii ― At Hawaiian Eye 2017, Michael S. Ip, MD, updates colleagues on the U.S.-based SCORE2 trial and the U.K.-based LEAVO trial, both of which ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Surgical robot successfully removes blood clot in patient with retinal vein occlusion  Healio

Blockage from a blood clot causing retinal vein occlusion in a patient was for the first time removed with the help of a surgical robot at the University Hospitals ...

Case Report Highlights Acute Central Retinal Vein Occlusion in Scleroderma Patient  Scleroderma News

Researchers in Saudi Arabia at King Fahd Hospital of the University and the University of Dammam reported a case of a male patient with scleroderma who was ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

New gene therapy for vision loss proven safe in humans  Medical Xpress

In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Comparison of VistaGen Therapeutics Inc. (VTGN) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)  Standard Recorder

Both VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are each other's competitor in the Biotechnology ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Allergan launches new surgical treatment for Glaucoma refractory to topical treatment in the United Arab Emirates  ZAWYA

XEN is a new minimally invasive option that provides an opportunity for refractory glaucoma patients The treatment system reduces intraocular pressure (IOP) in ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Vanda Pharmaceuticals Inc. (VNDA)'s Financial Results Comparing With Clearside Biomedical Inc. (NASDAQ:CLSD)  The FinReviewer

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Clearside Biomedical Inc. (NASDAQ:CLSD) compete with each other in the Biotechnology sector. We will ...

Risk Factors for Retinal Vein Occlusion  Medscape (subscription)

Is there a link between traditional risk factors for vascular disease and retinal vein occlusion?

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing ...

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

Ophthalmic Suspension Market to be driven by rising prevalence of eye diseases through 2023| Analysis with Top Key Players like ALLERGAN, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Falcon Group, Valeant and more  openPR

The suspension in the form of used to treat eye infections and related symptoms are generally termed as ophthalmic suspension. Generally it used in a ...

Can i buy viagra online with a prescription  Richardson Today

(2000) Hyperhomocystinemiain patients with nonarteritic anterior ischemic optic neuropathy,central retinal artery occlusion can i buy viagra online with a ...

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  Business Wire

Genentech's investigational Port Delivery System with ranibizumab (PDS) is a small, refillable device, slightly longer than a grain of rice, surgically implanted in ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Switching to Aflibercept Demonstrates Improvement in VA, CST for Poor Responders to Bevacizumab in SCORE2  MD Magazine

Those who were switched to aflibercept improved 9 letters of VA, and 110 µm in CST from months 6 to 12.

Catasys, Inc. (CATS) Reaches $12.89 After 6.00% Down Move; Shorts at Ohr Pharmaceutical (OHRP) Raised By 243.66%  The FinReviewer

The stock of Catasys, Inc. (NASDAQ:CATS) is a huge mover today! The stock decreased 5.18% or $0.7 during the last trading session, reaching $12.89.

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  AiThority

RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first mobile artificial intelligence (AI) app for eye care providers. The app can ...

Reviewing Wave Life Sciences Ltd. (WVE)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  Lives Advice

Wave Life Sciences Ltd. (NASDAQ:WVE) and Clearside Biomedical Inc. (NASDAQ:CLSD), both competing one another are Biotechnology companies. We will ...

Revealing the retina: Graphene corneal contact lens provides robust, irritation-free topographic electroretinography  Phys.org

Our vision can be damaged or lost by damage to the retina—a sensory membrane lining the back of the eye that senses light, converting the image formed into ...

Regeneron Pharmaceuticals Inc. (REGN)'s Financial Results Comparing With Homology Medicines Inc. (NASDAQ:FIXX)  The FinHeadLines

Since Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Homology Medicines Inc. (NASDAQ:FIXX) are part of the Biotechnology industry, they are ...

Novartis nAMD Treatment Brolucizumab Shows Superiority Against Regeneron's Eylea at Two Years  BioSpace

With *fresh* two-year data in hand, Novartis remains focused on seeking regulatory approval for brolucizumab, an ophthalmology drug for the treatment of ...

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

Bevacizumab, Ranibizumab Biosimilars Proven Effective, Safe for Retina Diseases  MD Magazine

The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.

Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron  Seeking Alpha

Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Associated Press

This *content* is a press release from our partner BusinessWire. The AP newsroom and editorial departments were not involved in its creation.

Reviewing OHR Pharmaceutical Inc. (OHRP)'s and Wave Life Sciences Ltd. (NASDAQ:WVE)'s results  The Yomi Blog

OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Wave Life Sciences Ltd. (NASDAQ:WVE) have been rivals in the Biotechnology for quite some time. Below is a ...

High Blood Pressure, High Cholesterol May Be Associated With Retinal Vascular Disease  Science Daily (press release)

High blood pressure and high cholesterol levels appear to be risk factors for retinal vein occlusion, a condition that causes vision loss, according to a new article.

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

Global Retinal Vein Occlusion Therapeutics Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2019 to 2023  Newz Base

The latest trending report Global Retinal Vein Occlusion Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023 offered ...

Cystoid Macular Edema Market Breakdown Data by End User, Types and Manufactures: Fovea Pharmaceuticals, Icon Bioscience, Merck  B2B Reports News

“Cystoid Macular Edema Market is a rising market in Medical Care sector at last five years (2013-2018). The Cystoid Macular Edema has covered fast ...

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

Contrasting of Clearside Biomedical Inc. (CLSD) and Homology Medicines Inc. (NASDAQ:FIXX)  Thе Mоnіtоr

Since Clearside Biomedical Inc. (NASDAQ:CLSD) and Homology Medicines Inc. (NASDAQ:FIXX) are part of the Biotechnology industry, they are influenced by.

Regeneron Pharmaceuticals Inc (REGN) is Wealthstreet Investment Advisors LLC’s 7th Largest Position  Highlight Press

Wealthstreet Investment Advisors LLC reduced its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 2.9% in the 4th quarter, according to its ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Increase in choroidal thickness seen after CPAP therapy  Healio

Patients with obstructive sleep apnea syndrome who underwent continuous positive airway pressure therapy experienced an increase in choroidal thickness ...

Regenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript  The Motley Fool

RGNX earnings call for the period ending December 31, 2018.

Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies  Zacks.com

Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA.

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

The eye jab that can banish blind spots  Daily Mail

Clive Woodington had Central Retinal Vein Occlusion (CRVO), a distressing condition that can lead to blindness in the affected eye.

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

Clearside Biomedical: Buy Or Sell Before 2018 Catalysts  Seeking Alpha

The 8-week data from the first phase 3 trial (SAPPHIRE) in treating macular edema due to retinal vein occlusion is expected in Q4 (a big binary event for the st.

» Load more